Repatha looks like a wonder drug until you do the math. This PCSK9 inhibitor can drive LDL cholesterol down by more than half, by blocking the PCSK9 protein that marks LDL receptors for degradation and letting the liver clear far more particles from the blood.

For people who get muscle aches on statins, that mechanism is a relief as much as a therapy. The drug bypasses the HMG‑CoA reductase pathway that statins hit, so the familiar cramps and weakness are far less common, while low‑density lipoprotein levels still fall to targets that many oral drugs cannot reach.

Yet the benefit is smaller than the dramatic lab numbers suggest. When trials added Repatha to background therapy, the relative drop in heart attack and stroke risk looked impressive, but the absolute risk reduction for most patients amounted to only a few fewer events per hundred treated, at high cost and with regular injections.

So the drug earns its place, just not for everyone. It makes the most clinical sense for people with very high baseline risk, established atherosclerotic cardiovascular disease, familial hypercholesterolemia, or genuine statin intolerance, where even a modest absolute gain can justify an aggressive biologic.